neurological disorders such as multiple sclerosis or peripheral neuropathy
And then I have to tell them, listen, your insurance is not going to cover it. Shah said this can be an especially frustrating situation for patients who are older and may not have the physical ability to exercise as much as they once did, so medication for weight loss could be an alternative option
Regulatory compliance answers whether a company can legally operate
Rights and permissions About this article Cite this article Tsambarlis, P., Levine, L.A
Tirzepatide the active ingredient in Mounjaro TM is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide1 (GLP1) receptor agonist (GIP/GLP1) approved for use as an adjunct to diet and exercise to improve glycemic control in patients with T2D
It has not (yet) been approved for weight management